A double-blinded, placebo-controlled trial of AR101, an oral immunotherapy drug treatment developed by Aimmune Therapeutics, shows promise in helping children with severe peanut allergy build tolerance to small amounts of peanut. The final results from the phase 3 trial demonstrated clinical desensitization to small amounts of peanut in the children and adolescents who participated.
Two percent of U.S. kids are allergic to peanuts, with the allergy being a leading cause of deadly anaphylaxis in children. It’s hoped that AR101, whose active ingredient is defatted peanut flour, will help protect children with severe peanut allergy from the risks inherent in accidental exposure. It is not a cure for peanut allergy.
The findings were presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting and published online in the New England Journal of Medicine.